What GO-ON Treats: Main Uses and Benefits

GO-ON (Sodium Hyaluronate) is a localized therapy used in managing the symptoms related to physical discomfort and symptoms that interfere with daily functioning often applied when discomfort and functional limitations negatively impact a patient’s daily routine. It may be considered relevant for the management of pain in osteoarthritis of the knee, hip, and shoulder.

The injections are typically indicated when conservative non-pharmacologic therapy and simple analgesics have not provided sufficient symptomatic relief.

Core Symptom Domains

This therapy is commonly used in situations involving certain distressing symptoms of osteoarthritis, such as chronic joint pain and stiffness. It is applied in addressing the persistent discomfort that often intensifies with movement and symptoms that create noticeable physiological strain. The treatment plays a role in managing this symptomatic burden, which contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

GO-ON is relevant for managing symptoms that interfere with daily functioning, such as reduced mobility and stiffness after rest. The therapy may assist with providing supportive relief when symptoms interfere with routine activities.

“The use of this therapy supports symptom management that may assist with maintaining functional stability and contribute to improved comfort when symptoms are more noticeable.”

This injection may be part of symptomatic management for patients whose mild to moderate symptoms are not adequately relieved by simple measures. It is applied in scenarios where additional management of discomfort is required, which may help patients cope more steadily with symptom fluctuations before considering other clinical interventions.

---

Quick Fact: Symptomatic Support for Functional Strain

GO-ON is relevant in conditions characterized by periods of heightened symptoms that lead to functional strain, offering a localized approach to manage discomfort and support mobility in the affected joint.

Regulatory References

1. U.S. Food and Drug Administration (FDA) regulatory summaries

Official Eligibility Rules for GO-ON (Sodium Hyaluronate)

The official eligibility profile for GO-ON is defined by regulatory agencies based on patient status, age, and joint condition. Use is contraindicated (absolutely prohibited) in patients with a known hypersensitivity to hyaluronate or any component of the preparation. Use is also strictly prohibited if there is an active infection either in the knee joint or at the intended injection site.

Populations Eligible for Use

GO-ON is indicated for use in adult patients who have been diagnosed with osteoarthritis of the knee. Eligibility often requires that the patient has not received adequate relief from standard conservative non-pharmacologic measures or simple pain relievers. If joint effusion (excess fluid) is present, official guidance requires its removal before administration.

Populations Where Use is Not Established

Safety and effectiveness have not been established in certain groups, meaning regulatory approval does not cover them. These include pediatric patients (under 21 years of age), pregnant women, and lactating women.

Comorbidity and Joint Restrictions

Restrictions apply to use in joints other than the knee, where effectiveness is not established. Caution is also advised in patients with severe active liver disease or severe renal insufficiency, as these populations were generally excluded from clinical trials.

Interactions with other medicines and products

The official interaction profile for GO-ON (Sodium Hyaluronate) is minimal, reflecting its function as a localized, intra-articular viscosupplementation agent with negligible systemic exposure. Regulatory documentation confirms the absence of conventional systemic drug-drug interactions, such as those involving enzyme-mediated metabolism or drug transporters.

Local Chemical Incompatibility

The primary documented restriction relates to specific substances used during the injection procedure. Co-administration of disinfectants containing Quaternary Ammonium Salts (such as benzalkonium chloride) is officially restricted. This is due to a documented local chemical incompatibility where the Sodium Hyaluronate solution may chemically precipitate or solidify upon contact with these substances. Some regulatory monographs also extend this precaution to disinfectants containing Chlorhexidine for the same reason.

Intra-Articular Co-Administration

Regarding other injections into the joint space, official regulatory information states that the safety and effectiveness of concomitant use with other intra-articular injectables (such as local anesthetics or corticosteroids) have not been established. This restriction is based on the lack of supporting clinical data. No specific timing separation rules for systemic medicines are documented, and no official interactions with food, alcohol, or herbal products are listed.

How GO-ON Works: The Mechanism of Action

Targeted Modulation of the Eicosanoid Pathway

GO-ON operates at the molecular level by selectively inhibiting the Cyclooxygenase-2 (COX-2) enzyme and acting as an antagonist on Prostaglandin E2 ( PGE2) receptors. This dual action targets both the enzymatic production and the downstream signaling of PGE2, a primary pro-inflammatory mediator within the Arachidonic Acid Cascade. This action reduces the concentration and signaling of PGE2 in the local tissue.

Interrupting Peripheral Pain Sensitization

The reduction in PGE2 initiates a mechanistic cascade that reduces the sensitization of peripheral pain-sensing neurons (nociceptors). By limiting the availability of PGE2 and blocking its binding to receptors, GO-ON modifies the early molecular steps that modulate nerve activity. This action influences the local physiological environment, adjusting the sensitivity threshold of nociceptors and modulating activity within the peripheral pain signaling pathway.

How to Use GO-ON

GO-ON (Sodium Hyaluronate) is a localized treatment defined by a fixed administration schedule and specific procedural requirements. Its use is characterized by its form as a specialized injectable solution.

Administration Scope

Instruction Entity	Detail
Route of administration	Intra-articular injection (direct delivery into the joint space).
Dosing schedule	A single injection contains 20 mg or 25 mg of Sodium Hyaluronate, administered to one joint per session.
Frequency and Course	Injections are administered once weekly. A full treatment course typically consists of three to five total injections over consecutive weeks.
Preparation Requirements	Administration requires the use of strict aseptic technique. Joint effusion (excess fluid) should be removed before the injection is administered.
Age-group rules	Safety and effectiveness have not been established for use in patients 21 years of age or younger.

Procedural Conditions

The procedure must be performed only by a licensed physician or qualified healthcare professional. Regarding skin preparation, disinfectants containing quaternary ammonium salts (such as benzalkonium chloride) must not be used, as they may cause the sodium hyaluronate to precipitate. The solution must be accurately placed within the joint capsule, avoiding surrounding tissues.

Following the procedure, patients are generally advised to avoid strenuous activity and limit prolonged or excessive weight-bearing on the injected joint for the 48 hours immediately after the procedure. The syringe is for single use only. The treatment cycle may be repeated as necessary based on professional assessment.

Evidence for Relief of Chronic Joint Discomfort

GO-ON was studied for outcomes related to physical discomfort in the joints. The main type of research was evaluated in randomized trials, which were designed to explore how outcomes related to physical discomfort compared to a non-active substance. These studies primarily focused on patient-reported outcomes describing perceived discomfort using standardized scales to assess how individuals experienced their symptoms.

The research examined how people rated their joint discomfort over defined time intervals. Data show patterns related to an observed difference in the reporting of discomfort compared to the control group. However, the nature and magnitude of these observed differences may vary across studies, and some studies showed patterns related to only modest change in the reporting of discomfort.

Evidence for Improvement of Mobility and Physical Function

Several trials were conducted during periods of increased symptom activity to see if GO-ON was associated with better movement and functional ability. Studies monitored outcomes reflecting daily functioning or activity level, such as the distance people could walk in a set time or their ability to perform routine tasks.

Data show patterns related to some measured changes in functional ability in participants who used GO-ON over defined time intervals. Research highlights changes measured during the study period where people reported an easier time with movement and physical tasks. However, findings were mixed across all functional measures; for instance, some objective tests of physical movement or speed appear to show no clear difference compared to the control groups.

Long-Term Studies and Follow-Up

The majority of current evidence for GO-ON is based on shorter-term trials that were observed in study periods of typically up to a few months. Therefore, long-term effects are not fully established. Evidence is limited for outcomes beyond six months of continuous use.

Common questions about GO-ON (FAQ)

Q: Is GO-ON the same type of medicine as [similar drug name]?

According to the official product information, GO-ON is classified as a viscosupplementation agent used for joint support. Its mechanism is primarily local and mechanical, acting as a lubricant and cushion directly within the knee joint. This means its classification and action are distinct from many other medicines that work systemically (throughout the whole body).

Q: What is the main difference between GO-ON and over-the-counter pain relievers?

The main difference lies in how the product works. GO-ON is a local treatment that physically restores lubrication and cushioning in the joint. In contrast, over-the-counter pain relievers, such as many analgesics, work systemically (throughout the body) by affecting pain and inflammation pathways.

Q: How long does GO-ON take to start working?

Studies have examined the timeline for relief after a GO-ON course is completed. The onset of observed benefits can vary significantly from one patient to another. Clinical trials typically monitor and measure effects starting several weeks after the full series of injections has been administered.

Q: Will I feel different right away when I start GO-ON?

Immediately after the injection, some patients report temporary, localized reactions at the injection site. These common effects can include discomfort, swelling, joint stiffness, or warmth. Regulatory documents indicate these localized events are typically transient and resolve spontaneously.

Q: Is GO-ON used for conditions other than its main approved purpose?

Official regulatory labels and product information specify the approved uses for GO-ON. Currently, the product is only approved for the treatment of pain associated with osteoarthritis of the knee.

Q: Why is it important to know my full medical history before taking GO-ON?

Providing a full medical history allows healthcare professionals to screen for important safety information. This is necessary to identify any contraindications, such as an infection in the joint, and to review specific warnings, which may include certain allergies or circulation problems.

Q: Can people with high blood pressure use GO-ON?

According to official product documents, high blood pressure (hypertension) is not listed as a specific contraindication or warning for the use of GO-ON.

Q: Is it normal to feel a bit tired when starting GO-ON?

Tiredness or fatigue is not typically listed as a common or uncommon adverse reaction in regulatory safety summaries. However, less frequent systemic side effects sometimes reported under Nervous System Disorders include headache or dizziness.

Q: Can elderly patients use GO-ON?

Official documentation indicates that the safety and effectiveness of GO-ON have not been specifically established in the geriatric population when compared directly to younger adults.

Q: How quickly does GO-ON leave the body after I stop taking it?

The active substance, Hyaluronic Acid, has a relatively short half-life in the joint, which is often measured in days. However, this measurement of the chemical component is separate from the product's clinical or therapeutic effect, which may last longer.

Q: Is GO-ON approved in the UK/Europe (EMA)?

Products containing the active substance, Sodium Hyaluronate, are widely authorized across Europe for specific uses. The substance itself is an established component and is described in the European Pharmacopoeia.

Q: Why is a prescription needed for GO-ON?

A prescription is required for GO-ON because of its specific route of administration. Official documents require it to be administered as an intra-articular injection (directly into the joint space) by a licensed physician or qualified healthcare professional.

Q: What are the rules about driving or operating machinery while on GO-ON?

Official regulatory documents recommend avoiding strenuous activity and limiting prolonged or excessive weight-bearing on the injected joint for the 48 hours immediately following the procedure. General warnings about driving or operating machinery beyond this time are not consistently noted in the official guidance.

Q: What is the legal classification of GO-ON (e.g., controlled substance)?

GO-ON is typically classified by regulatory agencies as a medical device or a non-controlled medicinal product. Because it is a local viscosupplementation agent and is not psychoactive, it is not classified as a controlled substance.

Q: How long does the main effect of one dose of GO-ON last?

The observed clinical effect following a full course of GO-ON treatment has been reported in some studies to last for up to 6 months. Research findings may vary, and official information describes this duration as an observed clinical effect in some studies.

Q: Why does GO-ON have a warning about heart conditions?

While a specific heart warning is not a common regulatory feature for this product, some clinical trials excluded patients with a history of cardiovascular disease. Official information indicates that the safety and effectiveness of the product have not been established in this specific patient population.

Q: Are there different versions of GO-ON (generic vs. brand)?

The active ingredient, Sodium Hyaluronate, is used in multiple different brand-name products that are available globally. These products may differ in their specific formulation, concentration, or molecular weight of the Hyaluronic Acid component.

Q: Does GO-ON affect my blood sugar levels?

Some clinical trials excluded patients with conditions such as diabetes or high blood sugar from participating. This indicates that the safety and effectiveness of GO-ON have not been established in this patient population in the available research.

Q: Is GO-ON linked to any dependency concerns?

GO-ON is classified by regulatory agencies as a local viscosupplementation agent. It is not classified as a controlled substance, and because its action is local and non-psychoactive, it is not associated with dependency concerns.

Q: Does GO-ON have any effects on hormone levels?

Direct effects on hormone levels are not typically listed as a side effect for this product. However, some clinical trials excluded patients using hormonal medications, suggesting a lack of established safety or efficacy data in this specific population.

Q: Is GO-ON prescribed by general practitioners or specialists?

The procedure is required to be performed by a licensed physician or qualified healthcare professional. Due to the specialized nature of the intra-articular injection, the product is typically prescribed and administered by specialists like orthopedic surgeons or rheumatologists.

GO-ON must be stored and disposed of strictly according to the official instructions detailed in regulatory labeling to maintain product stability and ensure public safety.

Item	Official Regulatory Requirement
Storage Temperature	Store at a temperature below 25 C; the product must not be frozen.
Protection	Must be kept in the original container and protected from light.
Child Safety	Store out of the sight and reach of children.
Disposal of Unused Product	Discard according to local requirements for pharmaceutical waste.
Disposal of Sharps	The used syringe must be placed immediately in a puncture-resistant sharps disposal container.

The official storage conditions are necessary to maintain the physical stability of the viscoelastic solution. Disposal instructions include both a general requirement for discarding unused medicine following local regulations and a specific mandate for sharps waste management to prevent injury.